Zealand Pharma A/S (22Z.SG)
- GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 25 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 12, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by per
- GlobeNewswire
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results
Press Release – No. 4 / 2024 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results Copenhagen, Denmark, May 9, 2024 – Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 16, 2024, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter of 2024. Presenting dur
- GlobeNewswire
Correction to Company announcement – No. 23 / 2024
Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely as
